A Big Day For Drug Pricing: Senate Hearing Will Overlap With House Committee’s
Senate Finance Committee's Jan. 29 witnesses will include economists, a patient advocate and “others,” to be announced in the coming days, panel says.
You may also be interested in...
Manufacturers will avoid direct interrogation in first round, but Oversight Committee also seeking information from sponsors on reasons behind price increases. In US Senate, Susan Collins writes to HHS Secretary Alex Azar urging the department to move ahead with rebate reform.
A key figure in determining what Rx bills advance in Congress, Grassley recently expressed interest in working with House Democrats in a floor speech on his drug pricing priorities.
President Trump is highlighting drug pricing as an area where he may be able to work with the new Democratic majority in the House. The political wisdom of building common ground on the topic is hard to ignore – but the tempestuous personality of the President is still the overriding factor. Instead, focus on whether HHS can win some breathing room to keep going with administrative changes.